Drug‐Coated Balloon Intervention in Large Coronary Arteries: Immediate Procedural Results and One‐Year Follow‐Up
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1) , 6072388
Abstract
Background: Drug‐coated balloons (DCBs) are an established treatment for in‐stent restenosis and small‐vessel coronary disease, but evidence for large de novo coronary artery lesions remains limited. Methods: We prospectively evaluated patients undergoing percutaneous coronary intervention (PCI) with DCB for de novo lesions in large coronary arteries (reference vessel diameter ≥ 2.75 mm). All lesions underwent adequate predilatation, and DCBs were used as the definitive treatment strategy. Bailout stenting was performed in cases of significant recoil or flow‐limiting dissection. Outcomes included procedural success, in‐hospital complications, and major adverse cardiovascular events (MACEs) at 12‐month follow‐up, defined as cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization (TLR). Results: A total of 539 DCB‐treated lesions were evaluated, of which 451 were excluded. The final cohort comprised 88 de novo lesions in large coronary vessels from 75 patients. DCB‐only treatment was performed in 65.9%; 34.1% underwent additional PCI with stenting of nonindex lesions. Post‐DCB dissections occurred in 50% and were predominantly NHLBI type A. Stenting was required in three cases, including one acute vessel closure, one severe recoil with residual stenosis during the index procedure, and one early vessel closure 11 h after the index procedure requiring repeat PCI. Mean acute gain on QCA was 0.93 ± 0.45 mm. Complete 12‐month follow‐up was achieved in 100% of patients. MACE at 12‐month follow‐up occurred in 2.7% (2/75), comprising one non‐ST‐segment elevation myocardial infarction and one clinically driven TLR. TLR was 1.3% at 12 months. One noncardiac death occurred and was not included in the MACE endpoint. No stroke or major bleeding was observed. Conclusions: DCB angioplasty in selected de novo large coronary lesions was feasible and associated with high procedural success and favorable 1‐year outcomes. Larger studies with longer follow‐ups are warranted to confirm these findings.Keywords
This publication has 42 references indexed in Scilit:
- Drug‐Coated Balloon‐Based Versus Drug‐Eluting Stent‐Only Treatment for Large Vessel Coronary Artery DiseaseCatheterization and Cardiovascular Interventions, 2025
- Beyond the Incision: Understanding Catheter Induced Coronary Artery DissectionCurrent Treatment Options in Cardiovascular Medicine, 2025
- Drug-Coated Balloons for the Treatment of Coronary Artery DiseaseJAMA Cardiology, 2025
- Drug‐Coated Balloon‐Based Treatment of Left Main True Bifurcation LesionCatheterization and Cardiovascular Interventions, 2025
- Comparison Between Drug-Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis of RCT DataCardiovascular Drugs and Therapy, 2024
- Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practiceClinical Research in Cardiology, 2022
- A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo LesionsCardiovascular Drugs and Therapy, 2021
- Percutaneous coronary intervention with drug‐coated balloon‐only strategy in stable coronary artery disease and in acute coronary syndromes: An all‐comers registry studyCatheterization and Cardiovascular Interventions, 2018
- Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese instituteClinical Research in Cardiology, 2018
- Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary StentsJAMA, 2015